Is compounded semaglutide legal in 2026?
Yes, under the federal compounding rules, which got stricter once the shortage ended. Under section 503A of the federal drug law, a state-licensed pharmacy may compound semaglutide for an individual patient with a prescription. It may not compound "regularly or in inordinate amounts" products that are "essentially copies" of Ozempic or Wegovy.
A compounded product is not a copy when "a prescriber determines and documents" a change that "produces a significant difference" for "an identified individual patient," according to the FDA's statement updated April 1, 2026. A lower price is not a medical reason. The FDA has also said it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a product in a calendar month.
Outsourcing facilities (section 503B) may not compound semaglutide from bulk ingredients. In the FDA's words, "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list." Our 503A vs 503B guide explains the two kinds of pharmacy.
Compounded semaglutide is not a generic either. All FDA-approved semaglutide comes from Novo Nordisk: Ozempic, Wegovy and Rybelsus®. One company's generic semaglutide injection has only a tentative approval, dated April 7, 2026 (Drugs@FDA), and the FDA explains that a tentative approval "does not allow the applicant to market the generic drug product."
